SpringerLink
Log in

Neuropsychopharmacotherapy in Children and Adolescents

  • Reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 150 Accesses

Abstract

The high prevalence of mental health dysfunction in childhood and adolescence, together with the fact that many mental disorders in adulthood emerge and consolidate in this period, underlines the importance of effective and safe treatments. The present chapter on neuropsychopharmacotherapy summarizes and discusses the critical issues of efficacy, tolerability, and acceptability in the application of the major medication groups, i.e., psychostimulants, antidepressants, and antipsychotics, prescribed to children and adolescents. Relevant questions and evidence-based knowledge are presented, complemented by descriptions of expert experience in the context of the most prevalent indications for these medications. Treatment strategies for attention-deficit-hyperactivity disorder, anxiety, depression, obsessive-compulsive disorder, and psychosis are outlined. This chapter focuses particularly on age-specific aspects, such as consent, patient participation, and off-label use, but it also includes a discussion of the current evidence and guideline recommendations in treating young patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Altamura AC, Camuri G, Dell’Osso B. Duration of untreated illness and duration of illness in anxiety disorders: assessment and influence on outcome. Mod Trends Pharmacopsychiatry. 2013;29:111–8. https://doi.org/10.1159/000351950.

    Article  PubMed  Google Scholar 

  • Alvarez-Jiménez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37(3):619–30. https://doi.org/10.1093/schbul/sbp129.

    Article  PubMed  Google Scholar 

  • Arango C, Buitelaar JK, Fegert JM, Olivier V, Pénélaud PF, Marx U, Chimits D, Falissard B. Study Investigators. Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries. Lancet Psychiatry. 2021. https://doi.org/10.1016/S2215-0366(21)00390-4.

  • Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Leitlinie der Deutschen Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (DGKJP): Langfassung der interdisziplinären evidenz- und konsensbasierten Leitlinie (S3) für die Behandlung von depressiven Störungen bei Kindern und Jugendlichen. AWMF-Register Nr. 028-043. 2013. https://www.awmf.org/leitlinien/detail/ll/028-043.html. Accessed 8 Nov 2021.

  • Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Leitlinie der Deutschen Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (DGKJP), Deutschen Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) & Deutschen Gesellschaft für Sozialpädiatrie und Jugendmedizin: Langfassung der (S3) Leitlinie “Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter”. AWMF-Register Nr. 028-045. 2018. https://www.awmf.org/leitlinien/detail/ll/028-045.html. Accessed 8 Nov 2021.

  • Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Leitlinie der Deutschen Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (DGKJP): Langversion der interdisziplinären evidenz- und konsensbasierten S3-Leitlinie für Diagnostik und Therapie von Zwangsstörungen im Kindes- und Jugendalter. AWMF-Register Nr. 028-007. 2021. https://www.awmf.org/leitlinien/detail/ll/028-007.html. Accessed 8 Nov 2021.

  • Ardic UA, Ercan ES, Kutlu A, Yuce D, Ipci M, Inci SB. Successful treatment response with aripiprazole augmentation of SSRIs in refractory obsessive–compulsive disorder in childhood. Child Psychiatry Hum Dev. 2017;48(5):699–704. https://doi.org/10.1007/s10578-016-0694-8.

    Article  Google Scholar 

  • Austin A, Flynn M, Richards K, Hodsoll J, Duarte TA, Robinson P, Kelly J, Schmidt U. Duration of untreated eating disorder and relationship to outcomes: a systematic review of the literature. Eur Eat Disord Rev. 2021;29(3):329–45. https://doi.org/10.1002/erv.2745.

    Article  PubMed  Google Scholar 

  • Balan S, Hassali MA, Mak VS. Two decades of off-label prescribing in children: a literature review. World J Pediatr. 2018;14(6):528–40. https://doi.org/10.1007/s12519-018-0186-y.

    Article  PubMed  Google Scholar 

  • Ben Amor L. Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disord. 2012;138(Suppl):S22–30. https://doi.org/10.1016/j.jad.2012.02.030.

    Article  CAS  PubMed  Google Scholar 

  • Braüner JV, Johansen LM, Roesbjerg T, Pagsberg AK. Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol. 2016;36(5):500–7. https://doi.org/10.1097/JCP.0000000000000559.

    Article  CAS  PubMed  Google Scholar 

  • Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines, 4.1 Edition. Toronto: CADDRA; 2020. https://www.caddra.ca/canadian-adhd-practice-guidelines. Accessed 8 Nov 2021.

    Google Scholar 

  • Coghill D, Banaschewski T, Cortese S, Asherson P, Brandeis D, Buitelaar J, Daley D, Danckaerts M, Dittmann RW, Doepfner M, Ferrin M, Hollis C, Holtmann M, Paramala S, Sonuga-Barke E, Soutullo C, Steinhausen HC, Van der Oord S, Wong ICK, Zuddas A, Simonoff E. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). Eur Child Adolesc Psychiatry 2021. https://doi.org/10.1007/s00787-021-01871-x.

  • Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9–20. https://doi.org/10.1097/chi.0b013e31815b5cb1.

    Article  PubMed  Google Scholar 

  • Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry. 2011;72(5):655–70. https://doi.org/10.4088/JCP.11r07064.

    Article  PubMed  Google Scholar 

  • Correll CU, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G, Ostinelli EG, Zangani C, Fornaro M, Estradé A, Fusar-Poli P, Carvalho AF, Solmi M. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. 2021;20(2):244–75. https://doi.org/10.1002/wps.20881.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, **a J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–38. https://doi.org/10.1016/S2215-0366(18)30269-4.

    Article  PubMed  PubMed Central  Google Scholar 

  • Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry. 2010;196(6):434–9. https://doi.org/10.1192/bjp.bp.109.066217.

    Article  PubMed  PubMed Central  Google Scholar 

  • David CN, Greenstein D, Clasen L, Gochman P, Miller R, Tossell JW, Mattai AA, Gogtay N, Rapoport JL. Childhood onset schizophrenia: high rate of visual hallucinations. J Am Acad Child Adolesc Psychiatry. 2011;50(7):681–6. https://doi.org/10.1016/j.jaac.2011.03.020.

    Article  PubMed  PubMed Central  Google Scholar 

  • Díaz-Caneja CM, Espliego A, Parellada M, Arango C, Moreno C. Polypharmacy with antidepressants in children and adolescents. Int J Neuropsychopharmacol. 2014;17(7):1063–82. https://doi.org/10.1017/S1461145712001265.

    Article  PubMed  Google Scholar 

  • Dörks M, Langner I, Dittmann U, Timmer A, Garbe E. Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. Eur Child Adolesc Psychiatry. 2013;22(8):511–8. https://doi.org/10.1007/s00787-013-0395-9.

    Article  PubMed  Google Scholar 

  • Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD: current concepts and treatments in children and adolescents. Neuropediatrics. 2020;51(5):315–35. https://doi.org/10.1055/s-0040-1701658.

    Article  PubMed  PubMed Central  Google Scholar 

  • Driver DI, Thomas S, Gogtay N, Rapoport JL. Childhood-onset schizophrenia and early-onset schizophrenia spectrum disorders: an update. Child Adolesc Psychiatr Clin. 2020;29(1):71–90. https://doi.org/10.1016/j.chc.2019.08.017.

    Article  Google Scholar 

  • Egberts KM, Mehler-Wex C, Gerlach M. Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry. 2011;21(06):249–53. https://doi.org/10.1055/s-0031-1286291.

    Article  Google Scholar 

  • Egberts KM, Gerlach M, Correll CU, Plener PL, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleischhaker C, Häge A, Hellenschmidt T, Imgart H, Kaess M, Karwautz A, Kölch M, Reitzle K, Renner T, Reuter-Dang S-Y, Rexroth C, Schulte-Körne G, Theisen F, Walitza S, Wewetzer C, Fekete S, Taurines R, Romanos M. Serious adverse drug reactions in children and adolescents treated on- and off-label with antidepressants and antipsychotics in clinical practice. Pharmacopsychiatry. 2022; https://doi.org/10.1055/a-1716-1856

  • Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, Newcorn JH, Gignac M, Al Saud NM, Manor I, Rohde LA, Yang L, Cortese S, Almagor D, Stein MA, Albatti TH, Aljoudi HF, Alqahtani MMJ, Asherson P, Atwoli L, Bölte S, Buitelaar JK, Crunelle CL, Daley D, Dalsgaard S, Döpfner M, Espinet S, Fitzgerald M, Franke B, Gerlach M, Haavik J, Hartman CA, Hartung CM, Hinshaw SP, Hoekstra PJ, Hollis C, Kollins SH, Sandra Kooij JJ, Kuntsi J, Larsson H, Li T, Liu J, Merzon E, Mattingly G, Mattos P, McCarthy S, Mikami AY, Molina BSG, Nigg JT, Purper-Ouakil D, Omigbodun OO, Polanczyk GV, Pollak Y, Poulton AS, Rajkumar RP, Reding A, Reif A, Rubia K, Rucklidge J, Romanos M, Ramos-Quiroga JA, Schellekens A, Scheres A, Schoeman R, Schweitzer JB, Shah H, Solanto MV, Sonuga-Barke E, Soutullo C, Steinhausen HC, Swanson JM, Thapar A, Tripp G, van de Glind G, Brink WVD, Van der Oord S, Venter A, Vitiello B, Walitza S, Wang Y. The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789–818. https://doi.org/10.1016/j.neubiorev.2021.01.022.

    Article  PubMed  PubMed Central  Google Scholar 

  • Fortea A, Ilzarbe D, Espinosa L, Solerdelcoll M, de Castro C, Oriolo G, Sugranyes G, Baeza I. Long-acting injectable atypical antipsychotic use in adolescents: an observational study. J Child Adolesc Psychopharmacol. 2018;28(4):252–7. https://doi.org/10.1089/cap.2017.0096.

    Article  CAS  PubMed  Google Scholar 

  • Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011;21(8):621–45. https://doi.org/10.1016/j.euroneuro.2010.07.002.

    Article  CAS  PubMed  Google Scholar 

  • Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–72. https://doi.org/10.1177/0004867416641195.

  • Geller DA, March J, AACAP Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):98–113. https://doi.org/10.1016/j.jaac.2011.09.019.

    Article  Google Scholar 

  • Gerlach M, Mehler-Wex C, Walitza S, Warnke A, Wewetzer C, editors. Neuro-/Psychopharmaka im Kindes-und Jugendalter: Grundlagen und Therapie. Springer; 2016. https://doi.org/10.1007/978-3-662-48624-5.

    Book  Google Scholar 

  • Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164(9):1356–63. https://doi.org/10.1176/appi.ajp.2007.07030454.

    Article  PubMed  Google Scholar 

  • Goldstein BI, Sassi R, Diler RS. Pharmacologic treatment of bipolar disorder in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2012;21(4):911–39. https://doi.org/10.1016/j.chc.2012.07.004.

    Article  PubMed  Google Scholar 

  • Hetrick SE, Cox GR, Witt KG, Bir JJ, Merry SN. Cognitive behavioural therapy (CBT), third-wave CBT and interpersonal therapy (IPT) based interventions for preventing depression in children and adolescents. Cochrane Database Syst Rev. 2016;2016(8):CD003380. https://doi.org/10.1002/14651858.CD003380.pub4.

    Article  PubMed  PubMed Central  Google Scholar 

  • Howes OD, Whitehurst T, Shatalina E, Townsend L, Onwordi EC, Mak TLA, Arumuham A, O’Brien O, Lobo M, Vano L, Zahid U, Butler E, Osugo M. The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. World Psychiatry. 2021;20(1):75–95. https://doi.org/10.1002/wps.20822.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ivarsson T, Skarphedinsson G, Kornør H, Axelsdottir B, Biedilæ S, Heyman I, Asbahr F, Thomsen PH, Fineberg N, March J, Accreditation Task Force of The Canadian Institute for Obsessive Compulsive Disorders. The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: views based on a systematic review and meta-analysis. Psychiatry Res. 2015;227(1):93–103. https://doi.org/10.1016/j.psychres.2015.01.015.

    Article  CAS  PubMed  Google Scholar 

  • Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, Robinson DG. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiat. 2020;77(12):1217–24. https://doi.org/10.1001/jamapsychiatry.2020.2076.

    Article  Google Scholar 

  • Kotapati VP, Khan AM, Dar S, Begum G, Bachu R, Adnan M, Zubair A, Ahmed RA. The effectiveness of selective serotonin reuptake inhibitors for treatment of obsessive-compulsive disorder in adolescents and children: a systematic review and meta-analysis. Front Psych. 2019;10:523. https://doi.org/10.3389/fpsyt.2019.00523.

    Article  Google Scholar 

  • Lytle S, McVoy M, Sajatovic M. Long-acting injectable antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27(1):2–9. https://doi.org/10.1089/cap.2016.0055.

    Article  CAS  PubMed  Google Scholar 

  • March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA. 2004;292(7):807–20. https://doi.org/10.1001/jama.292.7.807.

    Article  CAS  PubMed  Google Scholar 

  • Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71(2):179–208. https://doi.org/10.2165/11585350-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  • Masi G, Pfanner C, Brovedani P. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. J Psychiatr Res. 2013;47(8):1007–12. https://doi.org/10.1016/j.jpsychires.2013.04.003.

    Article  PubMed  Google Scholar 

  • National Institute for Health and Care Excellence (UK) (NICE). Psychosis and schizophrenia in children and young people: recognition and management. London: National Institute for Health and Care Excellence (UK); 2016. https://www.nice.org.uk/guidance/cg155. Accessed 8 Nov 2021.

    Google Scholar 

  • National Institute for Health and Care Excellence (UK) (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline 87. London: National Institute for Health and Care Excellence (UK) & National Guideline Centre (UK); 2018. https://www.nice.org.uk/guidance/ng87. Accessed 8 Nov 2021.

    Google Scholar 

  • Perris F, Sampogna G, Giallonardo V, Agnese S, Palummo C, Luciano M, Fabrazzo M, Fiorillo A, Catapano F. Duration of untreated illness predicts 3-year outcome in patients with obsessive-compulsive disorder: a real-world, naturalistic, follow-up study. Psychiatry Res. 2021;299:113872. https://doi.org/10.1016/j.psychres.2021.113872.

    Article  PubMed  Google Scholar 

  • Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8. https://doi.org/10.1176/ajp.2007.164.6.942.

    Article  PubMed  Google Scholar 

  • Pratico AD, Longo L, Mansueto S, Gozzo L, Barberi I, Tiralongo V, Salvo V, Falsaperla R, Vitaliti G, La Rosa M, Leonardi S. Off-label use of drugs and adverse drug reactions in pediatric units: a prospective, multicenter study. Curr Drug Saf. 2018;13(3):200–7. https://doi.org/10.2174/1574886313666180619120406.

    Article  CAS  PubMed  Google Scholar 

  • Remschmidt H, Theisen F. Early-onset schizophrenia. Neuropsychobiology. 2011;66(1):63–9. https://doi.org/10.1159/000338548.

    Article  Google Scholar 

  • Rijcken CA, Monster TB, Brouwers JR. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol. 2003;23(6):657–9. https://doi.org/10.1097/01.jcp.0000096247.29231.3a.

    Article  CAS  PubMed  Google Scholar 

  • Schatzberg AF, DeBattista C. Manual of clinical psychopharmacology. 8th ed. Washington, DC: American Psychiatric Publishing; 2015.

    Book  Google Scholar 

  • Schröder C, Dörks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, Riedel O. Extent and risks of antidepressant off-label use in children and adolescents in Germany between 2004 and 2011. Pharmacoepidemiol Drug Saf. 2017;26(11):1395–402. https://doi.org/10.1002/pds.4289.

    Article  PubMed  Google Scholar 

  • Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214–32. https://doi.org/10.1002/wps.20765.

    Article  PubMed  PubMed Central  Google Scholar 

  • Storebø OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, Nilausen TD, Magnusson FL, Zwi M, Gillies D, Rosendal S, Groth C, Rasmussen KB, Gauci D, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203. https://doi.org/10.1136/bmj.h5203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Treatment for Adolescents with Depression Study (TADS) Team. The Treatment for Adolescents with Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry. 2009;166(10):1141–9. https://doi.org/10.1176/appi.ajp.2009.08111620.

    Article  Google Scholar 

  • Uhre CF, Uhre VF, Lønfeldt NN, Pretzmann L, Vangkilde S, Plessen KJ, Gluud C, Jakobsen JC, Pagsberg AK. Systematic review and meta-analysis: cognitive-Behavioral therapy for obsessive-compulsive disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2020;59(1):64–77. https://doi.org/10.1016/j.jaac.2019.08.480.

    Article  PubMed  Google Scholar 

  • van Schalkwyk GI, Lewis AS, Beyer C, Johnson J, van Rensburg S, Bloch MH. Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis. Expert Rev Neurother. 2017;17(10):1045–53. https://doi.org/10.1080/14737175.2017.1371012.

    Article  CAS  PubMed  Google Scholar 

  • Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:317. https://doi.org/10.1186/s12888-014-0317-5.

    Article  PubMed  PubMed Central  Google Scholar 

  • Walitza S, Romanos M, Greenhill L, Banaschewski T. Attention-deficit/hyperactivity disorders. In: Psychiatric drugs in children and adolescents. Vienna: Springer; 2014. p. 369–81. https://doi.org/10.1007/978-3-7091-1501-5_12.

    Chapter  Google Scholar 

  • Walitza S, Renner T, Romanos M. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung. In: Neuro-/Psychopharmaka im Kindes-und Jugendalter. Berlin/Heidelberg: Springer; 2016. p. 415–28. https://doi.org/10.1007/978-3-662-48624-5_12.

    Chapter  Google Scholar 

  • Walter HJ, Bukstein OG, Abright AR, Keable H, Ramtekkar U, Ripperger-Suhler J, Rockhill C. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020;59(10):1107–24. https://doi.org/10.1016/j.jaac.2020.05.005.

    Article  PubMed  Google Scholar 

  • Wehry AM, Beesdo-Baum K, Hennelly MM, Connolly SD, Strawn JR. Assessment and treatment of anxiety disorders in children and adolescents. Curr Psychiatry Rep. 2015;17(7):52. https://doi.org/10.1007/s11920-015-0591-z.

    Article  PubMed  Google Scholar 

  • Wohkittel C, Gerlach M, Taurines R, Wewetzer C, Unterecker S, Burger R, Schreck D, Mehler-Wex C, Romanos M, Egberts K. Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice. J Neural Transm. 2016;123(8):1021–31. https://doi.org/10.1007/s00702-016-1573-y.

    Article  CAS  PubMed  Google Scholar 

  • Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205–18. https://doi.org/10.1017/S1461145712001277.

    Article  CAS  PubMed  Google Scholar 

  • Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21(8):600–20. https://doi.org/10.1016/j.euroneuro.2011.04.001.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Child and Adolescent Psychiatry, Psychiatric University Hospital Zurich (PUK), Zurich, Switzerland

    Susanne Walitza, Gregor Berger, Daniel Geller & Lukasz Smigielski

Authors
  1. Susanne Walitza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregor Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Geller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lukasz Smigielski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Walitza .

Editor information

Editors and Affiliations

  1. Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Wuerzburg, Germany

    Peter Riederer

  2. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  3. Centre for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Germany

    Christian Riederer

Section Editor information

  1. Brain and Mind Centre and School of Medical Sciences (Neuroscience), Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, New South Wales, Australia

    Peter Riederer

  2. Center for Research Promotion and Support, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Walitza, S., Berger, G., Geller, D., Smigielski, L. (2022). Neuropsychopharmacotherapy in Children and Adolescents. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_270

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62059-2_270

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62058-5

  • Online ISBN: 978-3-030-62059-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation